Trending stocks today
ARS Pharmaceuticals (SPRY-Q)
NASDAQ:SPRY
14.02
0.02
(0.14%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
The experts suggest that the company ARS Pharmaceuticals, with symbol SPRY-Q, is a speculative investment due to its role in developing immunotherapy drugs. They emphasize the need for more pharmaceutical companies in this space, indicating potential growth opportunities. However, given the speculative nature of the stock, it's essential for investors to conduct thorough research before considering an investment in ARS Pharmaceuticals.
N/A
Unknown
- «
- ‹
- 1
- ›
- »
ARS Pharmaceuticals(SPRY-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
ARS Pharmaceuticals(SPRY-Q) Frequently Asked Questions
What is ARS Pharmaceuticals stock symbol?
ARS Pharmaceuticals is a American stock, trading under the symbol SPRY-Q on the NASDAQ (SPRY). It is usually referred to as NASDAQ:SPRY or SPRY-Q
Is ARS Pharmaceuticals a buy or a sell?
In the last year, 1 stock analyst published opinions about SPRY-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for ARS Pharmaceuticals.
Is ARS Pharmaceuticals a good investment or a top pick?
ARS Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for ARS Pharmaceuticals.
Why is ARS Pharmaceuticals stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is ARS Pharmaceuticals worth watching?
In the last year, there was no coverage of ARS Pharmaceuticals published on Stockchase.
What is ARS Pharmaceuticals stock price?
On 2024-12-06, ARS Pharmaceuticals (SPRY-Q) stock closed at a price of $14.02.
Speculative, but we need more pharma companies to make immunotherapy drugs.